Global Blood Therapeutics to start phase 3 study for GBT440 in sickle cell disease
Global Blood Therapeutics (GBT) will start a phase 3 clinical trial in December for GBT440 in adults and adolescents with sickle cell disease (SCD).
The company signed an agreement with the US Food and Drug Administration (FDA) regarding the trial’s design.
